This website is intended for UK healthcare professionals only Log in | Register

Tag Archives: dapagliflozin

March 2024 Br J Cardiol 2024;31:27 doi:10.5837/bjc.2024.010

Comparison between early and late dapagliflozin administration for decompensated heart failure

Takahiro Tokuda, Yoriyasu Suzuki, Ai Kagase, Hiroaki Matsuda, Akira Murata, Tatsuya Ito

Abstract

Introduction Dapagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, was first used as a type 2 diabetes drug. However, in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure (DAPA-HF) trial, dapagliflozin effectively reduced both hospitalisations due to heart failure (HF) and death in patients with HF with reduced ejection fraction (HFrEF).1 Therefore, the European Society of Cardiology (ESC) and Japanese Circulation Society (JCS) guidelines recommended the administration of SGLT2 inhibitors to patients with HFrEF.2,3 Moreover, dapagliflozin suppressed both renal failure exacerbation and all-cause death in patie

| Full text

January 2023 Br J Cardiol 2023;30:21–5 doi:10.5837/bjc.2023.002

Evaluating initiation and real-world tolerability of dapagliflozin for the management of HFrEF

Alyson Hui Ling Tee, Gayle Campbell, Andrew D’Silva

Abstract

Introduction The prevalence of heart failure (HF) in the UK is estimated to be 920,000, with 200,000 new diagnoses every year.1 HF is the most common cause of admission for people over 65 years old and accounts for 2% of the National Health Service (NHS) total budget, which is approximately £2 billion. Seventy per cent of these costs are attributed to HF hospitalisation, amounting to £3,796 per episode of HF hospital admission, based on an average length of stay of 13 days.2 Additionally, untreated heart failure with reduced ejection fraction (HFrEF) has a mortality rate of approximately 40%,3,4 therefore, evidence-based pharmacological tre

| Full text

April 2021 Br J Cardiol 2021;28:56–61 doi:10.5837/bjc.2021.018

Eligibility for dapagliflozin in unselected patients hospitalised with decompensated heart failure

Hibba Kurdi, Parin Shah, Simon Barker, Daniel Harris, Benjamin Dicken, Carey Edwards, Geraint Jenkins

Abstract

(more…)

| Full text

December 2020

Dapagliflozin approved in the EU for heart failure

BJC Staff

Abstract

The EU approval is based on positive results from the landmark DAPA-HF phase III trial, published in The New England Journal of Medicine (DOI: 10.1056/NEJMoa1911303) and follows the recommendation for approval by the Committee for Medicinal Products for Human Use of the European Medicines Agency. Dapagliflozin is the first SGLT2 inhibitor to have shown a statistically significant reduction in the risk of the composite of cardiovascular death or worsening of heart failure events, including hospitalisation for HF.

| Full text

August 2017 Br J Cardiol 2017;24:(3) Online First

BCS 2017: spotlight on heart failure

BJC Staff, Dr Richard Crawley, Dr Brian Halliday, Dr Rosita Zakeri

Abstract

Landmark trials in heart failure – 30 years from CONSENSUS With 2017 marking the 30th year since the publication of CONSENSUS,1 which first reported a reduction in mortality with enalapril versus placebo in patients with advanced heart failure (HF), the BCS held a dedicated session to review the seminal clinical trials and advances in chronic heart failure management in this period. Dr Rosita Zakeri (Royal Brompton Hospital, London) reviewed this session for us and spoke to the BJC afterwards. Rosita Zakeri The era of vasodilator therapy for heart failure began in the 1990s. Professor Karl Swedberg (University of Gothenberg, Sweden) began

| Full text
Drugs for diabetes: part 8 SGLT2 inhibitors

March 2012 Br J Cardiol 2012;19:26–9 doi:10.5837/bjc.2012.005

Drugs for diabetes: part 8 SGLT2 inhibitors

Alison MacEwen, Gerard A McKay, Miles Fisher

Abstract

Introduction Type 2 diabetes mellitus is a major risk factor for developing both microvascular (retinopathy, nephropathy and neuropathy) and macrovascular complications (coronary heart disease, cerebrovascular disease and peripheral vascular disease).1 The link between maintaining good glycaemic control and prevention of these complications is well established.2-4 Guidelines recommend a target glycosylated haemoglobin (HbA1c) of 7% or less, but a large number of patients fail to meet this target and, as of yet, no ideal pharmacological blood glucose-lowering agent exists. Existing pharmacological therapies, which have been previously describ

| Full text

For healthcare professionals only

Add Banner

Close

You are not logged in

You need to be a member to print this page.
Find out more about our membership benefits

Register Now Already a member? Login now
Close

You are not logged in

You need to be a member to download PDF's.
Find out more about our membership benefits

Register Now Already a member? Login now